ITGA4 and Duchenne muscular dystrophy: In this context, CD49dhigh cells can be used as a prognostic marker of disease progression and CD49d inhibitors can be envisioned as a therapeutic approach to decrease inflammation-mediated tissue damage (see Figure 1), with consequent amelioration in the quality of life in DMD patients.